Schoen Klinik Hamburg Eilbek
- Address
- Dehnhaide 120, Abteilung für Rheumatologie, Haus 8, Zimmer 211, 22081 Hamburg, Germany
Schoen Klinik Hamburg Eilbek - Pediatric Rheumatology Research
Schoen Klinik Hamburg Eilbek is actively engaged in advancing therapeutic options for pediatric rheumatologic conditions. The center demonstrates particular expertise in evaluating novel biologic therapies for children and adolescents with complex autoimmune disorders, contributing valuable data to improve treatment outcomes in young patients.
- Juvenile psoriatic arthritis treatment research
- Biologic therapy evaluation in pediatric populations
- Pharmacokinetic and immunogenicity studies
The research center focuses on comprehensive evaluation of subcutaneous biologic agents, including ustekinumab and guselkumab, specifically tailored for pediatric patients with active juvenile psoriatic arthritis. This work encompasses critical assessment of efficacy, safety profiles, and pharmacokinetic characteristics unique to younger populations, helping to establish evidence-based treatment protocols for children with inflammatory arthritis conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Schoen Klinik Hamburg Eilbek
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous Ustekinumab and Guselkumab in Pediatric Patients with Active Juvenile Psoriatic Arthritis | Janssen Cilag International | Phase III | Not Recruiting | Apr 2023 | May 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Guselkumab | 1 | Unknown | 2023-04-20 | 2023-04-20 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.